Insider Transactions in Q3 2022 at Cardinal Health Inc (CAH)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2022
|
Christine Mundkur Director |
BUY
Grant, award, or other acquisition
|
Direct |
466
+50.0%
|
-
|
|
Sep 15
2022
|
Sujatha Chandrasekaran Director |
BUY
Grant, award, or other acquisition
|
Direct |
466
+50.0%
|
-
|
|
Sep 15
2022
|
Michelle Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
466
+50.0%
|
-
|
|
Sep 15
2022
|
Steven Barg Director |
BUY
Grant, award, or other acquisition
|
Direct |
466
+50.0%
|
-
|
|
Aug 15
2022
|
Stephen M Mason CEO, GMPD Segment |
SELL
Payment of exercise price or tax liability
|
Direct |
22,579
-19.48%
|
$1,557,951
$69.32 P/Share
|
|
Aug 15
2022
|
Stephen M Mason CEO, GMPD Segment |
BUY
Grant, award, or other acquisition
|
Direct |
17,150
+12.89%
|
-
|
|
Aug 15
2022
|
Brian S Rice Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,850
-20.65%
|
$679,650
$69.32 P/Share
|
|
Aug 15
2022
|
Jason M. Hollar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,206
-5.28%
|
$566,214
$69.32 P/Share
|
|
Aug 15
2022
|
Jason M. Hollar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,322
+35.17%
|
-
|
|
Aug 15
2022
|
Ola M Snow Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,803
-20.14%
|
$883,407
$69.32 P/Share
|
|
Aug 15
2022
|
Ola M Snow Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,004
+13.6%
|
-
|
|
Aug 15
2022
|
Michele Holcomb EVP - Strategy & Corp. Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
9,687
-17.88%
|
$668,403
$69.32 P/Share
|
|
Aug 15
2022
|
Michael C Kaufmann CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
168,214
-12.48%
|
$11,606,766
$69.32 P/Share
|
|
Aug 15
2022
|
Michael C Kaufmann CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
96,291
+12.49%
|
$3,755,349
$39.81 P/Share
|
|
Aug 15
2022
|
Victor L. Crawford CEO, Pharmaceutical Segment |
SELL
Payment of exercise price or tax liability
|
Direct |
29,952
-22.08%
|
$2,066,688
$69.32 P/Share
|
|
Aug 15
2022
|
Victor L. Crawford CEO, Pharmaceutical Segment |
BUY
Grant, award, or other acquisition
|
Direct |
17,150
+11.22%
|
-
|
|
Aug 15
2022
|
Patricia M English Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,313
-12.73%
|
$90,597
$69.32 P/Share
|
|
Aug 15
2022
|
Patricia M English Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,144
+17.21%
|
-
|
|
Aug 15
2022
|
Jessica L Mayer Chief Legal/Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,212
-6.35%
|
$1,256,628
$69.32 P/Share
|
|
Aug 15
2022
|
Jessica L Mayer Chief Legal/Compliance Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
442
+0.35%
|
$17,238
$39.81 P/Share
|
|
Aug 15
2022
|
Jessica L Mayer Chief Legal/Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,721
+9.86%
|
-
|
|
Aug 09
2022
|
Stephen M Mason CEO, GMPD Segment |
BUY
Grant, award, or other acquisition
|
Direct |
29,893
+23.23%
|
-
|
|
Aug 09
2022
|
Brian S Rice Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+21.79%
|
-
|
|
Aug 09
2022
|
Jessica L Mayer Chief Legal/Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,250
+15.37%
|
-
|
|
Aug 09
2022
|
Michael C Kaufmann CEO |
BUY
Grant, award, or other acquisition
|
Direct |
132,857
+16.49%
|
-
|
|
Aug 09
2022
|
Ola M Snow Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,607
+23.66%
|
-
|
|
Aug 09
2022
|
Jason M. Hollar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,999
+21.08%
|
-
|
|
Aug 09
2022
|
Michele Holcomb EVP - Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+19.69%
|
-
|
|
Aug 09
2022
|
Victor L. Crawford CEO, Pharmaceutical Segment |
BUY
Grant, award, or other acquisition
|
Direct |
36,536
+23.57%
|
-
|